BEAM - Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05 revenue of $16.65M beats by $7.21M
- Beam Therapeutics press release ( NASDAQ: BEAM ): Q2 GAAP EPS of -$1.02 misses by $0.05 .
- Revenue of $16.65M beats by $7.21M .
- Cash, cash equivalents and marketable securities were $1.2 billion as of June 30, 2022, as compared to $965.6 million as of December 31, 2021.
For further details see:
Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M